Genta presents tesetaxel dose-ranging trial results at ASCO 2010

[News]

Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.

More... (http://www.news-medical.net/news/20100608/Genta-presents-tesetaxel-dose-ranging-trial-results-at-ASCO-2010.aspx)